Abstract: Human leukocytes, which contain monocytes and neutrophils that exhibit chemotaxis to N-formylmethionine-leucine-phenylalanine (FMLP), were fused with the mouse macrophage RAW264-TG3 cell line which exhibits chemotaxis to endotoxin-activated mouse serum (EAMS) but not to FMLP. From such fusions twelve cell lines were isolated, all of which migrated to EAMS. Four of the cell lines also exhibited chemotaxis to FMLP, and of these cell lines only one, WBC264-9, retained the capacity to migrate to FMLP after culture for 20 or more passages. WBC264-9 exhibits chemotaxis to FMLP and provides a novel system to investigate attractant-specific biochemical reactions necessary for chemotaxis.

Abstract: Immortalized cell lines have been produced that secrete human monoclonal antibodies capable of binding to bacterial species which are a major cause of neonatal sepsis and meningitis. These antibodies have been found to be protective against lethal challenges of these bacteria, which include group B streptococcus, E. coli, K1, and Neisseria meningitidis group B. Pharmaceutical compositions containing these antibodies, which can be in combination with other monoclonal anitbodies, blood plasma fractions and antimicrobial agents, and the prophylactic and therapeutic use of such compositions in the management of infections, are included.

Abstract: Murine hybridomas are disclosed which were constructed by fusing spleen cells from BALB/c mice immunized with soluble crystal protein from Bacillus thuringiensis subsp. israelensis (B.t.i.) to the murine myeloma cell line SP2/0-AG14. An ELISA (enzyme-linked immunosorbent assay) method for detection of antibodies specific for crystal protein of B.t.i. was modified to produce 100- to 1,000-fold increased sensitivity and was used to identify hybridomas secreting monoclonal antibody specific for the B.t.i. crystal protein. Analysis of the hybridoma culture supernatant fluid indicated production of monoclonal IgG3 antibodies, specific for the 68,000 dalton protein presumed to be the insecticidal delta-endotoxin of B.t.i.

Abstract: The present invention is directed to monoclonal antibodies and hybridomas which produce them, which react with IgE when it is unbound and thereby inhibit IgE binding to mast cells, and react with IgE when it is bound to the B-cell FcE receptor, but do not react with IgE when it is bound to the mast cell FcE receptor.

Abstract: Monoclonal antibodies to adenocarcinoma cells, and, in particular, breast carcinoma cells, are produced by a hybridoma formed by fusing mouse lymphocytes and mouse myeloma cells. The monoclonal antibodies are capable of shrinking solid tumors associated with human breast. The monoclonal antibodies identify an antigen associated with carcinomas of ductal lineage. The monoclonal antibodies, specifically, F36/22 monoclonal antibodies, can be used diagnostically and therapeutically.

Abstract: Monoclonal antibodies demonstrating reactivity to genus-specific epitopes present on outer membrane proteins of bacteria of the genus Legionella and hybridomas for secreting the antibodies are disclosed.

Abstract: A hybrid cell line capable of producing monoclonal antibodies uniquely specific to human neutrophils. The monoclonal antibody has no reactivity with other human peripheral blood cells and virtually no reactivity with granulocyte precursors or other cells in bone marrow. Further, there is no reactivity with human acute leukemia cells. One of the partners in the hybridoma fusion of a mouse spleen cell developed from using highly purified human granulocytes as the immunization agent. The monoclonal antibody further is characterized by its capability of being used to enumerate and isolate neutrophils in normal peripheral blood and patients with acute leukemia.

Abstract: Human cancer is diagnosed/monitored by measuring the levels of N-[9-(.beta.-D-ribofuranosyl)purin-6-ylcarbamoyl]-L-threonine (t.sup.6 A), in a physiological fluid specimen of a subject by a quantitative immunoassay that employs a monoclonal anti-t.sup.6 A antibody and comparing that level to the level of t.sup.6 A that occurs in corresponding physiological fluid of normal subjects to determine whether the former is substantially elevated over the latter or by comparing that level to the level of t.sup.6 A present in specimens taken from the subject at different times.

Abstract: Monoclonal antibodies capable of immunoprecipitating labeled dihydropyridine receptor material from digitonin-solubilized skeletal muscle triads are disclosed. Said antibodies recognize a 170,000 dalton protein subunit of the dihydropyridine receptor.

Abstract: Two novel cell lines, ATCC #HB-8963 and ATCC #HB-8964 produce monoclonal antibody to human kininogen. One of the antibodies specifically recognizes the heavy chain of high and low molecular weight kininogen (the later protein is identical to alpha cysteine protease inhibitor). The other antibody recognizes the light chain of high molecular weight kininogen. The hybridomas are formed by fusing spleen cells from immunized BALB/c AnSkh mice with P3X63Ag8 or SP2/0-Ag14 myeloma cells. Diagnostic, therapeutic and biochemical uses of the monoclonal antibodies are provided.

Abstract: This invention relates to a novel epithelial cell line, a process for the preparation of the cell line, and its use in an in vitro bioassay for dioxinlike activity based on alterations in the cell line proliferation and morphology. The proprietary cell line of this invention exhibits a dioxin-induced, reversible, postconfluent inhibition of cell proliferation and a characteristic dioxin-induced flat-cell morphology.

Abstract: A monoclonal antibody specific for an .alpha..sub.1 -acid glycoprotein or for at least one antigenic determinant included in a sugar chain of the following formula: ##STR1## wherein Gal means galactose, GlcNAc means N-acetylglucosamine, Man means mannose, Fuc means fucose, and n is 0 or 1, which is useful for the measurement of glycoproteins in cells, tissues and blood and therefore is useful for diagnosis of various diseases, particularly tumors, and a method for the production thereof by fusing a neoplasm cell line with antibody-producing cells from an animal which has been immunized against an desialylated glycoprotein and culturing the resultant hybridoma.

Abstract: A monoclonal antibody raised to colorectal carcinoma, and a hybridoma which elicits the antibody, have been produced. This antibody, ND4 has been discovered to react with a new tumor marker, a glycoprotein of approximately 160 kD found on the surface of undifferentiated colorectal carcinoma cells; it does not cross-react with other known tumor markers. It is useful for detecting and monitoring colorectal carcinoma.

Abstract: Hybridoma cell lines that produce monoclonal antibodies that differentially recognize glycolipids with mono-, di-, and trifucosylated type 2 chain structures are disclosed. The monoclonal antibodies can be used to detect specific types of tumor cells that are characterized by enrichment in mono-, di-, or trifucosylated type 2 chain structure. As such, the antibodies produced by the hybridoma cell lines are useful for diagnosis and treatment of human cancer. Also disclosed is an improved method of raising hybridoma cell lines by selecting the hybridomas by positive reactivity with one or more fucosylated type 2 chain structures selected from the group consisting of III.sup.3 FucnLc.sub.4, V.sup.3 FucnLc.sub.6, III.sup.3 FucnLc.sub.6, III.sup.3 V.sup.3 Fuc.sub.2 nLc.sub.6, and III.sup.3 V.sup.3 VII.sup.3 Fuc.sub.n nLc.sub.8.

Abstract: Disialosyl Le.sup.a (IV.sup.3 NeuAcIII.sup.6 NeuAcIII.sup.4 FucLc.sub.4), a novel human cancer-associated fucoganglioside that is highly immunogenic. Also, a hybridoma cell line (ATCC No. HB 8861)secreting a monoclonal IgG3 antibody (FH7) directed to disialosyl Le.sup.a. The disialosyl Le.sup.a antigen was detected in various cancer tissues and their cell lines but was absent in various normal tissues and blood cells. Sera of patients with various cancers, particularly early cases of colonic and gastric cancers, showed an elevated disialosyl Le.sup.a antigen level, which subsequently decreased after surgical tumor removal.

Abstract: Human-nonhuman heterohybridomas capable of expressing IgM type antibodies can be screened to select hybridomas expressing IgM antibodies comprising human J chain components. Method comprises contacting separate samples of IgM antibodies (or IgM J chain components) from a given cell line with anti-human J chain antibodies and anti-non-human J chain antibodies to determine which antibody complexes with the J chain component of the samples, thereby identifying and permitting the early selection of a heterohybridoma expressing IgM having a human J chain component.

Abstract: A hybrid cell line yields a monoclonal antibody which is highly restricted to B-lineage lymphoblastic leukemia cells and their progenitors.